Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
Journal
European journal of haematology
Journal Volume
109
Journal Issue
3
Pages
205
Date Issued
2022-09
Author(s)
Kulasekararaj, Austin G
Griffin, Morag
Langemeijer, Saskia
Usuki, Kensuke
Kulagin, Alexander
Ogawa, Masayo
Yu, Ji
Mujeebuddin, Arshad
Nishimura, Jun-Ichi
Lee, Jong Wook
Peffault de Latour, Régis
301/302 Study Group
Abstract
The complement component 5 (C5) inhibitor ravulizumab demonstrated non-inferiority to eculizumab following 26 weeks of treatment in complement inhibitor-naïve and complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years.
Subjects
breakthrough hemolysis; complement inhibitor; lactate dehydrogenase; paroxysmal nocturnal hemoglobinuria; ravulizumab
Publisher
WILEY
Type
journal article